Related Experiment Video
Updated: Jun 20, 2026

Non-invasive Imaging of Disseminated Candidiasis in Zebrafish Larvae
Published on: July 30, 2012
Invasive zygomycosis in neonates and children
E Roilides1, T E Zaoutis, T J Walsh
13rd Department of Paediatrics, Aristotle University, Thessaloniki, Greece. roilides@med.auth.gr
Insights
Invasive zygomycosis presents differently in neonates and children compared to adults, with gastrointestinal and cutaneous forms being most common. Early antifungal therapy and surgery improve survival rates for this life-threatening fungal infection.
Area of Science:
- Mycology
- Pediatric Infectious Diseases
- Neonatology
Background:
- Invasive zygomycosis, a serious fungal infection, affects neonates and children differently than adults.
- Understanding age-specific patterns is crucial for diagnosis and treatment.
Purpose of the Study:
- To compare invasive zygomycosis in neonates and children with adult cases.
- To identify risk factors and effective management strategies.
Main Methods:
- Systematic literature review of PubMed and reference lists for English-language case reports and series.
- Inclusion criteria for neonatal (<1 month) and pediatric (<=18 years) cases.
- Comparison of findings with published adult zygomycosis data.
Main Results:
- 59 neonatal and 187 pediatric cases were analyzed.
- Gastrointestinal (54%) and cutaneous (36%) zygomycosis were most common in neonates, differing from adult sinopulmonary/rhinocerebral patterns.
- Mortality rates were high: 64% in neonates, 56% in children, and 53% in adults. Dissemination and young age (<1 year) were independent risk factors for death in children.
Conclusions:
- Zygomycosis is a life-threatening infection in pediatric populations with distinct clinical presentations.
- Combination therapy with amphotericin B and surgery demonstrated protective effects against mortality.
- Prompt diagnosis and aggressive management are essential for improving outcomes in neonates and children.
Abstract:
Invasive zygomycosis in neonates and children has both similarities to and differences from that in adults. We searched PubMed and individual references for English-language reports of single cases or case series of neonatal (<1 month) and paediatric (< or =18 years) zygomycosis and compared the results with published results in adults. Cases were included if they fulfilled pre-specified criteria. A total of 59 cases of neonatal zygomycosis were reported to July 2007; 157 paediatric cases were published up to 2004 and an additional 30 paediatric cases were reported more recently. Prematurity was a major underlying factor among neonatal cases. The most common manifestations of zygomycosis were gastrointestinal (54%) and cutaneous (36%). This pattern differs from the sinopulmonary and rhinocerebral patterns typical in older children and adults. Overall mortality was 64% in neonates, 56% in children and 53% in adults. A tendency for dissemination was higher in neonates than adults. Dissemination and young age (<1 year) were independent risk factors for death in children. Most patients who survived received antifungal therapy. Surgery combined with antifungal therapy was a protective factor against death. Most neonates and children who survived had received an amphotericin B formulation. Zygomycosis is a life-threatening infection in children and neonates with differing patterns of involvement in individuals of different ages. The most common management strategy in survivors involved a combination of amphotericin B and surgery.
Related Concept Videos
Cryptococcal Meningitis
Fungal Group Zygomycota
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Bacterial Meningitis I: Introduction
Cytomegalovirus Disease

